Kev Txhim Kho Kev Ua Haujlwm Zoo ntawm PROTAC: Kev Tshawb Fawb Tshiab
Kev siv cov tshuaj me me uas ua rau cov protein puas tsuaj, xws li PROTACs (PROteolysis TArgeting Chimeras), yog ib txoj kev kho mob tshiab los ntawm kev ua kom cov protein ua rau muaj kab mob puas tsuaj sai. Txoj kev no muab ib txoj kev qhia tshiab zoo rau kev kho ntau yam kab mob, suav nrog mob qog noj ntshav.
Muaj kev nce qib tseem ceeb hauv daim teb no tau luam tawm tsis ntev los no hauv phau ntawv xov xwm Nature Communications rau lub Xya Hli 2. Txoj kev tshawb fawb, coj los ntawm pab pawg kws tshawb fawb, tau txheeb xyuas ntau txoj hauv kev teeb tsa cellular uas tswj hwm qhov kev puas tsuaj ntawm cov protein tseem ceeb xws li BRD4, BRD2/3, thiab CDK9 siv PROTACs.
Txhawm rau txiav txim siab seb cov kev intrinsic no cuam tshuam li cas rau kev puas tsuaj ntawm cov protein, cov kws tshawb fawb tau tshuaj xyuas seb puas muaj kev hloov pauv hauv kev puas tsuaj ntawm BRD4 thaum muaj lossis tsis muaj MZ1, uas yog CRL2VHL-based BRD4 PROTAC. Cov kev tshawb pom qhia tau hais tias ntau txoj hauv kev intrinsic cellular yuav tiv thaiv BRD4-targeted degradation, uas tuaj yeem tiv thaiv los ntawm cov tshuaj inhibitors tshwj xeeb.
Cov Ntsiab Lus Tseem Ceeb: Cov kws tshawb nrhiav tau lees paub ntau yam tshuaj ua cov khoom ua rau kev puas tsuaj, suav nrog PDD00017273 (ib qho PARG inhibitor), GSK2606414 (ib qho PERK inhibitor), thiab luminespib (ib qho HSP90 inhibitor). Cov txiaj ntsig no qhia tau tias ntau txoj hauv kev cellular intrinsic cuam tshuam rau qhov ua tau zoo ntawm kev puas tsuaj protein ntawm ntau kauj ruam.
Hauv HeLa hlwb, nws tau pom tias PARG inhibition los ntawm PDD tuaj yeem txhim kho qhov kev puas tsuaj ntawm BRD4 thiab BRD2/3 tab sis tsis yog ntawm MEK1/2 lossis ERα. Kev tshuaj xyuas ntxiv tau qhia tias PARG inhibition txhawb nqa kev tsim ntawm BRD4-MZ1-CRL2VHL ternary complex thiab K29/K48-txuas ubiquitination, yog li ua kom yooj yim rau cov txheej txheem puas tsuaj. Tsis tas li ntawd, HSP90 inhibition tau pom tias txhim kho BRD4 degradation tom qab-ubiquitination.
Kev Nkag Siab Txog Mechanistic: Txoj kev tshawb fawb no tau tshawb nrhiav cov txheej txheem uas ua rau cov teebmeem no, qhia tau tias PERK thiab HSP90 inhibitors yog cov txoj hauv kev tseem ceeb uas cuam tshuam rau kev puas tsuaj ntawm cov protein los ntawm lub cev ubiquitin-proteasome. Cov inhibitors no hloov kho cov kauj ruam sib txawv hauv cov txheej txheem puas tsuaj uas tshwm sim los ntawm cov tshuaj lom neeg.
Ntxiv mus, cov kws tshawb nrhiav tau tshawb nrhiav seb cov tshuaj PROTAC puas tuaj yeem ua kom cov tshuaj degraders muaj zog ua haujlwm tau zoo dua. SIM1, uas yog ib qho trivalent PROTAC uas nyuam qhuav tsim tawm, tau pom tias ua rau muaj kev tsim cov BRD-PROTAC-CRL2VHL complex thiab tom qab ntawd degradation ntawm BRD4 thiab BRD2/3. Kev sib xyaw ua ke SIM1 nrog PDD lossis GSK ua rau muaj kev tuag ntawm cov hlwb zoo dua li siv SIM1 ib leeg.
Txoj kev tshawb fawb kuj pom tias PARG inhibition tuaj yeem ua rau tsis tsuas yog cov protein BRD tsev neeg xwb tab sis kuj tseem ua rau CDK9 puas tsuaj, qhia txog kev siv tau dav dua ntawm cov kev tshawb pom no.
Cov Kev Cuam Tshuam Yav Tom Ntej: Cov kws sau ntawv ntawm txoj kev tshawb fawb no xav tias kev kuaj ntxiv yuav txheeb xyuas cov kab mob ntxiv uas pab txhawb kev nkag siab txog cov txheej txheem rhuav tshem cov protein. Cov kev nkag siab no tuaj yeem ua rau kev tsim cov tswv yim kho mob zoo dua rau ntau yam kab mob.
Siv rau: Yuki Mori et al. Cov kev taw qhia intrinsic signaling pathways modulate targeted protein degradation. Nature Communications (2024). tsab xov xwm tag nrho https://www.nature.com/articles/s41467-024-49519-z
Txoj kev tshawb fawb no qhia txog lub peev xwm ntawm PROTACs hauv kev siv kho mob thiab qhia txog qhov tseem ceeb ntawm kev nkag siab txog cov kab ke cellular signaling kom txhim kho kev ua haujlwm ntawm kev rhuav tshem cov protein.